Peter H. Kraus

TL;DR: The topography of cerebral volume changes associated with Huntington’s disease can be mapped using VBM and it can be shown that cerebral grey matter changes co-vary with clinical severity and CAG repeat length.

TL;DR: A randomized double‐blind trial of riluzole in Huntington's disease finds the efficacy of this antiexcitotoxic drug in slowing disease progression is investigated.

TL;DR: It is found that oxidative function is impaired to a similar extent in manifest HD patients and asymptomatic mutation carriers and this suggests that mitochondrial dysfunction is an early and persistent component of the pathophysiology of HD.

TL;DR: Frequency of anhedonia and depression was significantly reduced during treatment with pramipexole and future studies should further investigate antianhedonic efficacy of dopamine agonists including pramipingxole in depressed patients with Parkinson's disease.

TL;DR: The feasibility of a computer based at‐home testing device (AHTD) in early‐stage, unmedicated Parkinson's disease (PD) patients over 6 months is tested, and high patient compliance and satisfaction suggest the feasibility of its incorporation into larger clinical trials, especially when travel is difficult and early changes or frequent data collection are considered important to document.